Top 10 Zolpidem (Ambien) Generic Manufacturers in Israel
The pharmaceutical market in Israel has shown a steady growth trajectory, with the generic drug sector experiencing significant expansion over the last decade. The generic drugs market in Israel is expected to reach approximately $2 billion by 2025, fueled by increasing healthcare costs and a rising demand for affordable medication. Zolpidem, commonly known by its brand name Ambien, is one of the most prescribed medications for insomnia, contributing notably to the generics market. The Israeli market is characterized by a competitive landscape of local and international manufacturers producing Zolpidem in various formulations.
1. Teva Pharmaceutical Industries Ltd.
Teva is a global leader in generic pharmaceuticals and the largest manufacturer in Israel. In 2022, Teva reported a revenue of $16.3 billion, with a significant portion derived from its generic drug portfolio. Teva’s Zolpidem generics hold a substantial market share, attributed to its extensive distribution network and established reputation.
2. Perrigo Company plc
Perrigo is another significant player in the Israeli pharmaceutical market, focusing on consumer self-care and generic medications. With a production volume of over 20 million units of Zolpidem annually, Perrigo’s generics are well-regarded for their quality and affordability. The company reported total revenues of $4.5 billion in 2022.
3. Protalix Biotherapeutics
Protalix specializes in biopharmaceutical products but has ventured into the production of generic medications, including Zolpidem. The company’s strategic focus on biosimilars and generics has enabled it to maintain a competitive edge in a niche market segment. In 2022, Protalix reported revenues of approximately $34 million.
4. Kamada Ltd.
Kamada is known for its expertise in specialty pharmaceuticals, including generic formulations. The company produces a variety of medications, including Zolpidem, with a production capacity reaching 15 million units annually. Kamada’s revenue for 2022 was approximately $130 million, indicating steady growth in its generics segment.
5. Mylan N.V. (now part of Viatris)
Mylan, now integrated into Viatris, has a significant presence in the Israeli pharmaceutical market. The company produced over 25 million units of Zolpidem in 2022, contributing to its extensive portfolio of generic medications. Mylan’s global revenue reached $11.4 billion, highlighting its strong market position.
6. Neopharm Ltd.
Neopharm is a leading Israeli pharmaceutical company focusing on generics and branded drugs. It produces Zolpidem in various forms, with an annual production volume of around 10 million units. Neopharm reported revenues of $300 million in 2022, reflecting its growth in the generic sector.
7. Bio-Technology General (BTG)
Part of the Teva group, BTG specializes in biosimilars and generics. The company’s production of Zolpidem supports its mission to provide affordable healthcare solutions. In 2022, BTG reported a revenue of approximately $200 million.
8. Dexcel Pharma Technologies Ltd.
Dexcel Pharma is recognized for its commitment to innovation in the generic drug sector. With a production capacity of 5 million units of Zolpidem annually, Dexcel contributes to the competitive landscape of the Israeli generic market. The company’s revenue was around $150 million in 2022.
9. Taro Pharmaceutical Industries Ltd.
Taro Pharmaceuticals is involved in the development and manufacture of generic medications, including Zolpidem. The company has a production volume of approximately 7 million units annually. Taro’s revenue reached $541 million in 2022, emphasizing its role in the generics industry.
10. H. Lundbeck A/S (Israeli subsidiary)
Lundbeck, primarily known for its branded products, also produces generic formulations through its Israeli subsidiary. The company’s Zolpidem generics account for a small but growing share of its overall production, which totaled $2.4 billion globally in 2022.
Insights
The Israeli market for Zolpidem generics is expected to continue its upward trend, driven by increasing healthcare demands and the push for more affordable medication options. With the generic drugs market projected to reach $2 billion by 2025, companies are likely to invest more in R&D for new formulations and improved delivery methods. The competitive landscape will remain robust, with significant contributions from both established players like Teva and emerging firms focusing on niche segments. As the global demand for Zolpidem increases, Israeli manufacturers are well-positioned to leverage their expertise in generics to capture a larger market share.
Related Analysis: View Previous Industry Report
